Bevacizumab treatment also resulted in the upregulation of bFGF and of the MMP inhibitors TIMP-1 and TIMP-2, as a potential response to MMP upregulation in U87 and NSC23 glioblastoma cells, suggesting that tumors can overcome anti-VEGF treatment via the release of bFGFs from ECM with the help of MMPs, supporting an autocrine pattern of bFGF signal transduction that results in neovascularization [64]. Here, VEGFA is linked to glioblastoma.